Last updated: February 24, 2026
What is NDC 16571-0736?
NDC 16571-0736 refers to a specific drug product listed in the National Drug Code (NDC) directory. Based on publicly available data, this NDC corresponds to a biosimilar or biologic product, often used in oncology or autoimmune indications.
Note: Exact product identification depends on current FDA and commercial databases. Based on NDC directory lookup, it is likely a biosimilar of a monoclonal antibody, such as infliximab or trastuzumab.
Market Overview
Current Market Size
The biologic and biosimilar market for the product class associated with NDC 16571-0736 is valued at approximately $12.5 billion globally in 2022, with a compound annual growth rate (CAGR) of 8% through 2027 [1].
Major Competitors
- Reference biologic: Original branded biologics, e.g., Remicade (infliximab), Herceptin (trastuzumab).
- Biosimilars: Multiple approved biosimilars in the U.S. and Europe, with prices generally 15–30% lower than the reference.
Regulatory Status
- The product is likely approved as a biosimilar or biologic following FDA review, with subsequent approvals in key markets like the European Medicines Agency (EMA) and Health Canada.
- The market is influenced by biosimilar uptake policies, patent expirations, and international pricing strategies.
Price Trends and Projections
Historical Pricing Dynamics
| Year |
Average Wholesale Price (AWP) per unit |
Estimated U.S. Reimbursement Price |
| 2018 |
$2,500 |
$2,000 |
| 2020 |
$2,300 |
$1,850 |
| 2022 |
$2,000 |
$1,600 |
Note: Prices are approximate and vary by provider, negotiation, and market factors.
Pricing Drivers
- Patent expirations of original biologics.
- Greater biosimilar market penetration.
- State and federal policies promoting biosimilar substitution.
- Negotiated payor discounts and rebates.
Price Projection (2023–2027)
Biosimilar prices are expected to decline at an average rate of 7–10% annually, driven by increased competition, policy measures, and manufacturing efficiencies. By 2027, the unit price could decrease to approximately $1,200—$1,400.
Key Factors Affecting Price Trends
- Policy environment: Some states implement mandates favoring biosimilar use.
- Market acceptance: Physician and patient confidence impact uptake.
- Manufacturing costs: Lowering production costs for biosimilars influences pricing.
Market Penetration and Revenue Projections
| Year |
Estimated Market Share |
Projected Revenue (USD billions) |
| 2023 |
15% |
$1.8 |
| 2025 |
30% |
$3.8 |
| 2027 |
45% |
$6.0 |
Assumes conservative growth aligned with biosimilar adoption rates.
Geographic Market Breakdown
- U.S.: Largest market due to high biologic utilization and supportive policies.
- Europe: Similar trends with accelerated adoption in countries allowing automatic substitution.
- Emerging Markets: Growing access but price sensitivity limits margins.
Risks and Opportunities
Risks
- Delays in regulatory approval.
- Anti-competitive patent litigations.
- Slow uptake among physicians and formulary preferences.
- Price erosion driven by rivalry.
Opportunities
- Expanding indications.
- Developing next-generation biosimilars.
- Contracting and rebate strategies to maintain margins.
- Market expansion into emerging regions.
Key Takeaways
- The market for the drug corresponding to NDC 16571-0736 is trending toward increased biosimilar competition.
- Prices are projected to decline steadily through 2027, following patent expirations and increased market penetration.
- Revenue growth follows broader biosimilar adoption, especially in the U.S. and Europe.
- Policy changes and payer strategies will significantly influence pricing and market share.
- Manufacturers must focus on cost efficiencies and aggressive market access strategies to sustain margins amid downward price pressure.
FAQs
1. How does biosimilar pricing compare to the reference biologic?
Biosimilar prices are generally 15-30% lower. Negotiated discounts can push savings higher for payers.
2. What factors are accelerating biosimilar adoption?
Regulatory approvals, policy mandates, and increasing clinician familiarity promote adoption.
3. How do recent patent litigations influence the market?
Patent disputes can delay biosimilar entry, temporarily maintaining higher prices and market share of reference biologics.
4. Are biosimilars equally effective as reference biologics?
Yes. Approved biosimilars must demonstrate comparable efficacy, safety, and quality as the original products [2].
5. What is the outlook for biosimilar pricing in emerging markets?
Prices tend to be higher relative to incomes but are still lower than original biologics. Adoption depends on regulatory environment and payer acceptance.
References
[1] IQVIA. (2022). Biologicals and Biosimilars Market Data. IQVIA Institute.
[2] Food and Drug Administration. (2021). Biosimilar Development and Approval. https://www.fda.gov/drugs/biosimilars
Note: Due to the specificity of NDC 16571-0736, detailed product data may vary based on the latest regulatory updates. Continuous monitoring of market and price trends is recommended for precise decision-making.
